Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?

Core Insights - Gilead Sciences, Inc. (GILD) is facing competitive pressures in its cell therapy franchise, which includes Yescarta and Tecartus, leading to a 7% year-over-year sales decline to $1.8 billion in 2025 [1][9] - To address this decline, GILD plans to acquire Arcellx for $7.8 billion, which will enhance its control over the anito-cel therapy and streamline development and commercialization [2][4][9] Sales Performance - Sales from GILD's cell therapy unit decreased by 7% year-over-year to $1.8 billion in 2025, with Yescarta sales down 5% to $1.5 billion and Tecartus sales down 15% to $344 million [1][9] - The decline is attributed to increasing competition from both in-class and out-of-class therapies [1][9] Acquisition Strategy - GILD's acquisition of Arcellx is valued at $115 per share in cash plus a $5 contingent value right, totaling an equity value of $7.8 billion [2] - This acquisition will provide GILD full control over anito-cel, eliminating profit-sharing and enhancing long-term margin potential [4] Pipeline Developments - GILD's subsidiary, Kite, is collaborating with Arcellx to co-develop anito-cel, which has received FDA acceptance for a biologics license application as a treatment for relapsed or refractory multiple myeloma, with a decision expected in December 2026 [3][4] Competitive Landscape - GILD faces strong competition in the cell therapy market from companies like Bristol Myers (BMY) and Novartis (NVS), with BMY's Breyanzi surpassing $1 billion in annualized sales in 2025 [6][7] - NVS's Kymriah recorded sales of $381 million in 2025, reflecting a 14% decline due to competitive pressures [8] Financial Performance - GILD's shares have increased by 30.3% over the past year, outperforming the industry growth of 15.4% [11] - The current price/earnings ratio for GILD is 16.41x forward earnings, higher than its historical mean of 11.32x but lower than the large-cap pharma industry average of 17.89x [13] Earnings Estimates - The bottom-line estimate for GILD in 2026 has increased to $8.66 from $8.60, while the estimate for 2027 has risen to $9.63 from $9.33 [14]